Statins do not cause the majority of the conditions that have been listed in their package leaflets, including memory loss, ...

Emerging from stealth, the company is debuting NEXUS, a Large Tabular Model (LTM) designed to treat business data not as a ...

Eli Lilly’s Zepbound is still viewed as the leading weight-loss shot, according to a ...

Establishment Labs Holdings has 20% market share and 25% revenue growth while hitting positive cash flow and high margins.

Doctors, patients and researchers are at the very beginning of understanding how the new class of obesity drugs interact with eating disorders.

Obesity is a common risk factor for various long-term conditions (LTCs), according to a February study published in Nature Communications.

Q4 2025 earnings call recap: revenue surge, 2026 guidance, Mounjaro/Zepbound momentum, pricing risks, and Medicare access—read now.

The judge who sentenced Robert Dindinger worried that his former patients may question whether they can trust other therapists. “Will they turn away the very help they need because of you?” the judge ...

Higher BMI was linked to worse biopsychosocial PROs and greater opioid use among patients requiring spine care.

Consumers can walk into their local coffee shop, where the barista knows their name and order, or use an app that already anticipates their needs. They can log into a streaming service that predicts ...